KALV
Income statement / Annual
Last year (2026), KalVista Pharmaceuticals Inc's total revenue was $73.62 M,
and the percentage change from the previous year is not available.
In 2026, KalVista Pharmaceuticals Inc's net income was -$164.29 M.
See KalVista Pharmaceuticals Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2026
|
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
12/31/2025 |
04/30/2025 |
04/30/2024 |
04/30/2023 |
04/30/2022 |
04/30/2021 |
04/30/2020 |
04/30/2019 |
04/30/2018 |
04/30/2017 |
| Operating Revenue |
$73.62 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$12.69 M |
$16.13 M |
$8.39 M |
$1.50 M |
| Cost of Revenue |
$6.08 M
|
$0.00
|
$86.17 M
|
$0.00
|
$0.00
|
$41.29 M
|
$40.19 M
|
$35.02 K
|
$18.24 K
|
$12.67 K
|
| Gross Profit |
$67.54 M
|
$0.00
|
-$86.17 M
|
$0.00
|
$0.00
|
-$41.29 M
|
-$27.50 M
|
$16.09 M
|
$8.38 M
|
$1.49 M
|
| Gross Profit Ratio |
0.92
|
0
|
0
|
0
|
0
|
0
|
-2.17
|
1
|
1
|
0.99
|
| Research and Development Expenses |
$55.64 M
|
$71.71 M
|
$86.17 M
|
$80.28 M
|
$70.17 M
|
$41.29 M
|
$40.19 M
|
$35.02 M
|
$18.24 M
|
$12.67 M
|
| General & Administrative Expenses |
$0.00
|
$116.29 M
|
$54.28 M
|
$30.60 M
|
$26.45 M
|
$16.64 M
|
$13.03 M
|
$10.93 M
|
$8.86 M
|
$11.18 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$183.74 M
|
$116.29 M
|
$54.28 M
|
$30.60 M
|
$26.45 M
|
$16.64 M
|
$13.03 M
|
$10.93 M
|
$8.86 M
|
$11.18 M
|
| Other Expenses |
$0.00
|
$0.00
|
-$86.17 M
|
$0.00
|
$0.00
|
-$41.29 M
|
-$40.19 M
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$239.38 M
|
$188.00 M
|
$54.28 M
|
$110.87 M
|
$96.61 M
|
$16.64 M
|
$13.03 M
|
$45.95 M
|
$27.10 M
|
$23.84 M
|
| Cost And Expenses |
$245.46 M
|
$188.00 M
|
$140.45 M
|
$110.87 M
|
$96.61 M
|
$57.92 M
|
$53.22 M
|
$45.95 M
|
$27.10 M
|
$23.84 M
|
| Interest Income |
$8.68 M
|
$6.44 M
|
$3.90 M
|
$2.23 M
|
$1.09 M
|
$903.00 K
|
$1.83 M
|
$1.40 M
|
$82.00 K
|
$36.00 K
|
| Interest Expense |
$19.34 M
|
$5.79 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$1.45 M
|
$941.00 K
|
$816.00 K
|
$718.00 K
|
$564.00 K
|
$537.00 K
|
$512.00 K
|
$378.00 K
|
$180.00 K
|
$40.00 K
|
| EBITDA |
-$150.62 M |
-$173.33 M |
-$134.28 M |
-$94.37 M |
-$80.75 M |
-$57.39 M |
-$40.02 M |
-$29.44 M |
-$18.53 M |
-$22.30 M |
| EBITDA Ratio |
-2.05
|
0
|
0
|
0
|
0
|
0
|
-3.15
|
-1.83
|
-2.21
|
-14.83
|
| Operating Income Ratio |
-2.33
|
0
|
0
|
0
|
0
|
0
|
-3.19
|
-1.85
|
-2.23
|
-14.85
|
| Total Other Income/Expenses Net |
$420.00 K
|
$7.94 M
|
$5.35 M
|
$17.96 M
|
$14.27 M
|
$11.68 M
|
$11.54 M
|
$9.13 M
|
$2.90 M
|
$3.74 M
|
| Income Before Tax |
-$171.42 M
|
-$180.05 M
|
-$135.10 M
|
-$92.91 M
|
-$82.34 M
|
-$46.24 M
|
-$28.99 M
|
-$20.69 M
|
-$15.81 M
|
-$18.60 M
|
| Income Before Tax Ratio |
-2.33
|
0
|
0
|
0
|
0
|
0
|
-2.28
|
-1.28
|
-1.88
|
-12.37
|
| Income Tax Expense |
-$7.13 M
|
$3.39 M
|
-$8.45 M
|
$0.00
|
$0.00
|
$0.00
|
$124.00 K
|
$124.00 K
|
$0.00
|
$0.00
|
| Net Income |
-$164.29 M
|
-$183.44 M
|
-$126.64 M
|
-$92.91 M
|
-$82.34 M
|
-$46.24 M
|
-$29.12 M
|
-$20.82 M
|
-$15.81 M
|
-$18.60 M
|
| Net Income Ratio |
-2.23
|
0
|
0
|
0
|
0
|
0
|
-2.29
|
-1.29
|
-1.88
|
-12.37
|
| EPS |
-3.23 |
-3.69 |
-3.44 |
-3.33 |
-3.36 |
-2.33 |
-1.64 |
-1.38 |
-1.53 |
-1.92 |
| EPS Diluted |
-3.23 |
-3.69 |
-3.44 |
-3.33 |
-3.36 |
-2.33 |
-1.64 |
-1.38 |
-1.53 |
-1.92 |
| Weighted Average Shares Out |
$50.90 M
|
$49.65 M
|
$36.79 M
|
$27.89 M
|
$24.47 M
|
$19.09 M
|
$17.75 M
|
$15.08 M
|
$10.32 M
|
$9.71 M
|
| Weighted Average Shares Out Diluted |
$50.90 M
|
$49.65 M
|
$36.79 M
|
$27.89 M
|
$24.47 M
|
$19.09 M
|
$17.75 M
|
$15.08 M
|
$10.32 M
|
$9.71 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
